
1	Thiazolidinones: Potential human novel coronavirus (SARS-CoV-2)
2	Protease Inhibitors against COVID-19
3	
4	
5	Vijay Kumar Vishvakarma ^{1,2} , Indra Bahadur, ^{3,*} Kamlesh Kumari, ^{4,*} Prashant Singh ^{1,*}
6	
7	¹ Department of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New
8	Delhi, India; ² Department of Chemistry, University of Delhi, Delhi, India; ³ Department of
9	Chemistry, Faculty of Natural and Agricultural Sciences, North-West University, South
10	Africa; ⁴ Department of Zoology, Deen Dayal Upadhyaya College, University of Delhi, New
11	Delhi, India
12	
13	
14	*Corresponding author Email: <u>biotechnano@gmail.com; psingh@arsd.du.ac.in</u> and
15	<u>bahadur.indra@gmail.com</u>
16	

17 Abstract:

COVID-19 is a rapidly spreading infectious disease caused by a novel beta coronavirus 18 SARS-CoV-2. During the 1980's coronavirus, genomic RNA was transcribed into a set of 19 subgenomic mRNAs that encode viral proteins containing a leader sequence derived from the 20 21 5' end of the genome. The subgenomic mRNAs are transcribed from negative-strand RNAs, synthesized for the full-length genomic RNA - a unique mechanism, presumed to occur by a 22 process involving viral polymerase jumping from one part of the genome template to another, 23 leading to high rate of recombination for coronaviruses, playing role in viral interspecies 24 25 infections. The sequence of SARS-CoV-2 confined that spike protein has furin cleavage site in the S1/S2 junction different from SARS-CoV and other closely related viruses. This has 26 proved the possibility of Protease inhibitors as antivirals has led to the speculation about 27 virulence and pathogenesis, and it is also possible that this new furin site may serve as a 28 29 marker to identify a possible precursor virus. This novel human coronavirus (SARS-CoV-2) has resulted in a large number of fatalities and incapacitated human health system. No 30 treatment is available, and a vaccine will not be available for several months. Hence, the 31 protease of coronavirus is a promising target for antiviral drug discovery. 32

We herein report a new generation of thiazolidinone derivatives, inhibitors of SARS-CoV-2 33 34 coronavirus protease that incorporated thiazolidinone heterocycles as N-terminal capping groups of the peptide moiety. The compounds were extensively characterized with respect to 35 36 inhibition of various proteases, inhibition mechanism, membrane permeability, antiviral 37 activity. Our research group has recently designed a one-pot three-component reaction and its 38 mechanism was studied through DFT. Further, a library of the molecules based on the products is designed. These novel molecules were screened through ADMET and molecular 39 40 docking to find out the potential inhibitor of SARS-CoV-2 protease, as they may have competitive inhibition mechanisms, in correlation with their membrane permeability, a more 41 42 pronounced antiviral activity.



- 44 Keywords: SARS-CoV-2 protease; COVID-19; protease inhibitors; Docking; ADMET;
- 45 antiviral activity.

47 **1 Introduction**

Several virus replications inhibiting drugs were discovered during the 1950s. However, the 48 development of the new antiviral agents with activity against the virus-specific functions 49 grew rapidly in recent years and several different antiviral chemotherapeutic agents have 50 been approved for the treatment of individuals infected with a variety of different viruses 51 including respiratory syncytial virus. The virus contains nucleic acid genomes which undergo 52 replication as part of the virus life cycle. Therefore, the majority of the approved antiviral 53 agents are nucleoside analogues, and act by inhibiting viral DNA synthesis or viral reverse 54 55 transcription. The coronavirus is the world's only superpower today. December 2019 was a tragic day for the world when a new coronavirus caused an outbreak of pulmonary disease in 56 the city of Wuhan in China. This COVID-19 pandemic caused by SARS-CoV-2 is now a 57 global health emergency and is the greatest challenge, the world has faced since the second 58 world war since more than 150 countries are already gravely affected. On the turn of the 21st 59 century, researchers confronted to study coronaviruses - a family of enveloped positive-60 stranded RNA viruses with the question of coronavirus novelty with the severe acute 61 respiratory syndrome (SARS) as is the case with the current outbreak of SARS-CoV-2, the 62 causative agent of COVID-19. SARS-CoV-2 main proteinase controls the activities of the 63 64 corona replication complex is an attractive target for therapy. Coronaviruses (CoVs) have a single-stranded RNA genome (26.2-31.7kb) spherical and characterized by bears club-shaped 65 66 projections of glycoproteins on its surface. The structural proteins of CoV are spike (S) trimeric protein, membrane(M) protein, envelope (E) protein and the beta-CoVs also have 67 68 hemagglutinin esterase (HE) glycoprotein. The best-characterized drug targets among coronaviruses are the main protease, an enzyme essential for processing the polyproteins that 69 70 translated from viral RNA, chopping up the chain into functional proteins that the virus then 71 uses to assemble itself and multiply. If we disrupt this key piece of the virus's self-replication 72 machinery could bring an infection screeching to a halt. Hence inhibiting the activity of this enzyme would block viral replication, and in the absence of human proteases with cleavage 73 specificity, inhibitors are unlikely to be toxic.[1-3] Most of the experimental laboratories are 74 shut down due to novel coronavirus, SARS-CoV-2 spreading across the globe, stalled the 75 76 efforts to monitor the virus. However, some labs are looking for druggable targets to treat COVID-19, a viral infection in the absence of any specific vaccine or drugs. Thus protease 77 78 of SARS-CoV-2 is a promising target for antiviral drug discovery. [4-7] The imidazothiazole 79 derivatives have pharmacological properties, such as anti-infectious, antiviral and others. Our 80 research group is involved in the synthesis of heterocyclic compounds and evaluation of their

potential antiviral properties and other biological properties. One-pot multicomponent reactions are important in the present circumstances to synthesize thiazolidinones known for their antibacterial, antifungal, anticancer and antiviral activities by inhibiting the enzyme activities. Therefore, thiazolidinones have been prepared by one-pot multi-component reaction as inhibitors of SARS CoV-2 protease, may be a potential drug for treating COVID-19.[8-14]

Our in-silico approach provides a strategically efficient route to achieve as a potential 87 candidate and insight for inhibiting the protease activity and to control the infection caused 88 89 by SARS-CoV-2, as a fast and efficient approach. [4-6] Therefore, we have proposed a onepot multicomponent reaction via aromatic aldehydes, chromane-2,4-dione and thiazolidine-90 2,4-dione to get the potential molecule as a protease inhibitor. The reaction mechanism of the 91 synthesis has been studied by DFT. Further, a library of the compounds was designed to 92 study their impact on the protease activity of SARS-CoV-2 via docking or molecular 93 modeling. 94

95

96 **Result**

97 The docking of all the 100 designed compounds was performed against the protease of 98 SARS-COV-2 and the data is available in Table 3. Compound number 34, 42, 55, 58, 60 and 93 showed the best binding with the protease of SARS-COV-2. The details of the energy 99 100 contribution due to hydrogen bonding, electrostatic and van der Waal of the top six compounds is given in **Table 4**. Further, the drugs used in clinical trials are docked against 101 102 the protease of SARS-COV-2 and the binding energy was determined, given in Table 4a. The docked posed of the top six compounds 34, 42, 55, 58, 60 and 93 showed the best 103 104 binding with the protease of SARS-COV-2 are given in Figure 2. A details study of the interaction of the compounds number s34, 42, 55, 58, 60 and 93 against the protease of 105 106 SARS-COV-2 is given in Table 5. Herein, the interaction (hydrogen bonds and hydrophobic) of the compounds with different amino-acids of the protease of SARS-CoV-2 with their 107 distance is determined. Further, the top six compounds were analyzed by plotting the 108 interacted amino-acids of the protease on interaction with the energy as in Figure 3. 109

110

111 ADMET Result

Physiochemical properties act as descriptors to describe the properties of drug.[15] For drug
likeness and absorption, distribution, metabolism, excretion and toxicity (ADMET)
properties, these descriptors play key role.

115 Physicochemical properties of the top six hits

Aqueous solubility of drug is highly important to describe the absorption and distribution 116 properties. Poor solubility of drug mainly aims to bad absorption and leads to the failure of 117 drug.[16] Herein, log S values of the drugs were calculated based on the structural features. 118 Partition coefficient is defined as a ratio of concentrations of unionized compound among the 119 two solvents. If one solvent is polar like water and other is non-polar like octanol then it is 120 termed as lipophilicity or hydrophobicity.[16] Distribution coefficient (log D_{7.4}) is another 121 form of log P. The basic differences between log P and log D is that log D is pH specific and 122 123 also consider the ionic parts of drug while log P mainly consider neutral part.[17] The values of Log S, Log D7.4 and Log P are given in Table 6. 124

125

126 Absorption properties of the top six thiazolidinones

Based on the physicochemical descriptors, absorption properties in term of Caco-2 127 permeability, permeability glycoprotein (P-gp) for inhibitor and substrate, human intestinal 128 absorption and bioavailability (F20% & F30%) were studied and given in Table 7. Caco-2 129 cells are part of colon carcinoma and have resemblance with epithelium of intestine. Caco-2 130 permeability measures the rate of reflux of drug to cross the Caco-2 monolayer.[18] The 131 132 numerical value of Caco-2 permeability must be higher than -5.15 for the optimum permeability. The result the all the compounds have good permeability. Glycoprotein 133 134 permeability indicates the efflux and mediated by P-gp. P-gp efflux indicates the efflux from liver, kidney, gastrointestinal tract and brain endothelium.[19] All the compounds have 135 136 acceptable values.

137

138 Distribution properties of top six thiazolidinones

Distributional properties of top six thiazolidinones were calculated based on physicochemical
descriptors. The distribution properties like plasma protein binding (PPB), volume
distribution (VD) and blood brain barrier penetration (BBB) is given in Table 8.

When a drug reaches in blood it bind with plasma protein. The binding affinity of the compounds towards plasma proteins lowers its distribution through the cell membrane. Minimum the binding energy more efficient a drug will be.[20] All the compounds have acceptable PPB. Volume distribution is that volume of drug, which is necessary for a drug to maintain the sufficient concentration in the bloodstream. VD is responsible for the distribution of drug between plasma and rest of the body. More the value of VD, more will be the distribution of drug into the body tissue.[21] The values of VD < 0.07 L/kg correspond to

bind with plasma protein or highly hydrophilic, value of VD 0.07-0.7 L/kg corresponds to 149 evenly distributed and VD > 0.7 L/kg corresponds to distribution towards tissue components 150 (highly lipophilic). VD value indicates that all top-six compounds have high affinity towards 151 the plasma protein. Central nervous system (CNS) mainly controls the whole body activity 152 and blood-brain barrier (BBB) separate circulating blood of CNS from extracellular fluid of 153 all rest body part. Drugs can be categorized by targeting and non-targeting CNS. When 154 researchers developing non CNS targeting drug, it must be ensure that drug should not cross 155 the blood brain barrier. BBB crossing drug can cause more risk of side effect.[22] BB ratio > 156 157 0.1 is BBB+ and BB ratio <0.1 is BBB-. The features selected for BBB permeation is Hbonds < 8-10, MW < 400-500 and no acids. 158

159

160 Metabolism properties of top six thiazolidinones

Metabolism is break down of a compound within the body after entering in the body. 161 Metabolism of the drug/molecule is done in the liver by the redox enzymes. The most 162 common types of redox enzyme is cytochrome P450.[23, 24] These metabolites are two 163 164 types, pharmacologically active and inactive/ innert. In case of pharmacologically inert drug metabolism deactivates the amount of drug and resulted in the less effect by drug on the 165 166 body. In case of active metabolite, metabolism enhances the activity of drug more than the drug. Metabolic properties for top-six compounds were calculated for different isozymes of 167 168 cytochrome P450 in term of inhibitor and substrate. The main isozymes are CYP1A2, CYP3A4, CYP2C9, CYP2C19 and CYP2D6 and of 57 isozymes. These isozymes metabolize 169 170 about two-thirds drugs and these five isozymes mainly contribute to almost 80%. The values for top-six compounds in term of cytochromes substrate (sub) and inhibitors (inh) were 171 172 analyzed as in Table 9. All the compounds showed acceptable metabolic properties.

173

174 Excretion properties of top six thiazolidinones

Drug may be eliminated in its original state or eliminated after some modification. Excretion 175 of a drug is followed by several routs but through kidney and liver are considered best. 176 Excretion through renal duct is most common for the unchanged drug or its metabolites. Only 177 178 water soluble and polarized drugs are excreted with urine. [25, 26] Lipid soluble drugs can't be excreted by kidney. Hence, they require hepatic metabolism to break them into soluble 179 components to eliminate with urine. Hepatic metabolized drug are mainly excreted by the 180 faeces.[27] The excretion of drug is measure in two terms half-life $(t_{1/2})$ and clearance rate 181 182 (CL) and value for top-six compounds are given in Table 10.

The half-life of drug is time for the amount of drug reduced to its half. Basically drug excretion follows the first order kinetics. Hence, a graph between log of concentration of compound and time gives the values of clearance rate as a slope of graph. Half-life of excretion greater than 8 hours is high, 3-8 hours is moderate and less than 3h is low. All topsix compounds have half-life less than 3h. Clearance rate of excretion having values more than 15 is high, 15-5 is moderate and less than 5 is low. All top-six compounds follow low clearance rate.

190

191 Toxicity properties of top six thiazolidinones

It is highly challenging to develop a new drug without considering it toxicity properties. 192 Many drugs developed by researchers faced clinical trial unable to reach in market due to 193 undesired toxicity or side effect.[28] Optimizing drug likeness properties is the key to 194 develop the new lead out. Drug discovery mainly focused on the effective binding of drug 195 into the active site of receptor. Potency of drug is a key factor in early stage while toxicity 196 197 properties decide its effectiveness and success.[29] To develop a new drug, there must be a 198 fine balance between toxicity, potency and pharmacokinetics of drug. Toxicity is the potency of drug to damage the body parts of an organism. Based on the adverse effect of drug on the 199 200 various body parts it is divided into various forms like cytotoxicity, hepatotoxicity, etc.[29, 30] Herein, numerous toxicity of top-six compounds were determined like the human Ether-201 202 à-go-go-Related Gene (hERG) blockers, human hepatotoxicity (H-HT), ames mutagenicity, skin sensitization, half maximal lethal dose (LD50), drug induced liver injury (DILI) and 203 204 maximum recommended daily dose (FDAMDD) and the value are given in Table 11.

Human Ether-à-go-go-Related Gene (hERG) mainly encoded for the Kv11.1 protein part of 205 206 potassium ion channel (hERG channel). The activity of heart is mainly maintained by the electrical signal and this signal is mediated by hERG channel.[31] The highest values of 207 208 hERG blocker is found for 93 while the lowest for 58/60. Liver provide a clearance pass to orally administered drugs and toxins. The hepatocyte membrane is in close contact with the 209 drugs hence, a drug mainly infect the hepatocyte and can damage the liver. The highest 210 human hepatotoxicity (H-HT) value is found for F1 while lowest is for 34. The Ames test is 211 212 performed to check the carcinogenic nature of compounds because mutation is directly linked to the carcinogenicity.[32] The highest Ames mutagenicity values is found for A209 while 213 lowest Ames mutagenicity value is found for 42. Most of the drugs act as skin sensitizer and 214 produces irritation and sensitization. It is an immunological response to reduce the effect 215 produced by drug.[33] The highest skin sensitization value is found for 60/55/58 while the 216

217 lowest value is found for 93. Median lethal dose (LD_{50}) is the dose of drug responsible for the killing of 50 % population of the treated animals within the given time.[34] The highest 218 toxicity is found for 63. Drug induced liver injury (DILI) is the prime cause of failure of liver 219 in the recent time. Most of the lipophilic drugs are metabolized by the liver and they cause 220 221 some injury during this.[35] The highest value of DILI is found for F185 while lowest value is found for D46 & D20. The Food and Drug Administration (FDA) recommended maximum 222 daily dose (FDAMDD) of the database of about 1200 drugs and suggested for the new lead 223 drug to follow the QSAR model of FDAMDD.[36] The highest value of FDAMDD is found 224 225 for 93. The maximum upper limit of drug beyond which no side effect is recorded with proper efficacy is known as maximum recommended therapeutic dose (MRTD).[37] The 226 highest MRTD dose is found for 58/60. 227

228

229 Conclusion

Based on the previous results, different thiazolidinones are potential inhibitors against the 230 ns2b-ns3 protease of DENV. In the present, novel thiazolidinones were designed using one 231 pot three component reaction and the mechanism of synthesis was studied through DFT 232 approach. Their potential was check against the protease of SARS-COV-2 as well the results 233 234 were compared with the repurposing drugs being used in clinical trials against the infection of SARS-COV-2. COMD60 showed the best binding with the protease of SARS-COV-2 and 235 236 expected to be a potential antiviral agent. COMP60 also possess acceptable lipophilicity and solubility. Highest bioavailability is found to COMP60 and COMP58. Moderate distribution 237 238 and metabolism property was found for COMP60. Lowest LD50 value is found for COMP60. It also has less drug induced liver injury. ADMET results corroborate the docking result 239 240 towards the potency of COMP60.

241

242 Experimental details

243 Designing of molecules and molecular docking

244 **Designing of molecules**

Theoretically, design a one-pot three-component reaction using via by taking benzaldehyde,

chromane-2,4-dione and thiazolidine-2,4-dione (TZD) to get 7-phenyl-7,10-dihydro-6H,9H-

- chromeno[3',4':5,6]pyrano[2,3-d]thiazole-6,9-dione as in **Scheme 1**.
- 248
- 249

Proposed mechanism for the synthesis of 7-phenyl-7,10-dihydro-6H,9H-250 chromeno[3',4':5,6]pyrano[2,3-d]thiazole-6,9-dione 251

- Mechanism of synthesis of 7-phenyl-7,10-dihydro-6H,9H-chromeno[3',4':5,6]pyrano[2,3-252
- d]thiazole-6,9-dione was studied by the Gaussian 9.0 as in Scheme 2. Thiazolidine-2,4-dione 253
- (1) reacts with benzaldehyde (2) to given 3 after elimination of a water molecule. Further, 4hydroxy-2H-chromen-2-one (4) reacts with 3 and to give 5. Further, hydroxyl group attacks 255
- on the keto group within the molecule and results in formation of 6. Then, removal of water 256
- occurs in 5 to give 6, the molecule of interest. 257
- 258

254

Study the mechanism of synthesis by DFT 259

Density functional theory (DFT) uses the quantum mechanical approach to solve the 260 Schrodinger equation for the N body electron system. It reduces the wave function to achieve 261 the soluble solution. By solving the electron density wave function equation of N electron 262 system, various energy state of the system with physiochemical parameters can be 263 determined. The optimization of product, reactants and intermediated were performed by 264 applying B3LYP theory and taking 6–311G as a basis set in Gaussian 9.0.[38] The values of 265 HOMO and LUMO were calculated by DFT and used to calculate the physicochemical 266 267 descriptors.[39-43] The HOMO is filled with the electron and donate the electron. While LUMO is empty and accept electron. The energy gap between HOMO and LUMO is known 268 269 as HOMO~LUMO gap. The optimized energies of the reactant, intermediate and product molecule are used to describe the proposed mechanism of reaction for the synthesis of novel 270 271 thiazolidine. DFT approach is used to optimize the molecules. The optimized energy of TZD (1) is found to -719.4 A.U. while the energy of benzaldehyde was found to -345.48 A.U. The 272 273 product of 1 & 2 is 3 having energy value -988.87 A.U. suggested the formation of a stable 274 product. 3 reacts with 4 having energy -572.26 and form an intermediate 5 having energy -275 1560.93 A.U. 5 goes chelation by the attack of lone pair of OH to the carbonyl group and form the stable intermediate 6 with energy of -1560.93 A.U. 6 loses one water molecule to 276 give 7-phenyl-7,10-dihydro-6H,9H-chromeno[3',4':5,6]pyrano[2,3-d]thiazole-6,9-dione with 277 an energy of -1484.51 A.U. The increase in energy suggests the loss of water. A graphical 278 depiction of the energies of the reactants, intermediates and product is given in the Figure 1. 279 Details of the HOMO, LUMO, optimized geometry and various energies values of reactants, 280 intermediate and product are given in Table 1. 281

- 282
- 283

284 Derivatives of thiazolidinones based on Scheme 1

The parent compound was used to create the 99 virtual derivatives to screen against the protease of SARS-COV-2. **Scheme 2** contains benzaldehyde as one of the reactant and therefore, its derivatives are used to create the library as in **Table 2**. The potency of the designed molecules will be compared with the repurposing drugs used in the clinical trials.

289

290 Preparation of PDB of SARS-COV-2 main protease

The preparation of protease of SARS-COV-2 (PDB: ID- 6LU7) was done using UCSF Chimera 1.11.2 in the dock prep module. The replacement of incomplete residues, removal of solvents, adding hydrogen and charges were assigned according to the AMBER.ff14SB force field. All the designed moelcules were optimized and used for docking against the protease of SARS-COV-2. [44]

296

297 Molecular Docking

Molecular docking uses the computational tool to identify the interaction between small 298 molecules and a protein just like the lock and key model. It allows to studies the interaction at 299 atomic level in the active binding cavity of protein.[43, 45-58] Choosing a suitable parameter 300 to get the lead compound is very important.[59][59][57] iGEMDOCK has several parameters 301 and drug screening mode is used. [60] In this, population size (n = 200), number of solutions 302 for each compound (s = 3) and generations (g = 70) is considered. All the compounds were 303 docked against protease of SARS-COV-2 and top six compounds were selected based on 304 lowest energy.[39, 61, 62] The energy of binding of ligand to the protein is given by 305 306 **Equation 1**.

307

$E_{\text{Binding}} = H_{\text{bond}} + vdW + Elec \tag{1}$

H_{bond} stands for hydrogen bonding energy, vdW stands for van der Waal energy and Elec
stands for electro statistic energy.

310

311 **Post-Docking analysis and modeling**

The top molecules were chosen based on the total binding energy as per equation **1**. Post dock screening was performed by iGEMDOCK.[44] The modeling of best poses of molecules was taken by the Discovery Studio Visualizer V-2017.2 of BIOVIA.

- 315
- 316
- 317

318 **ADMET properties**

Physiochemical properties act as descriptors to describe the properties of drug. For drug 319 likeness and absorption, distribution, metabolism, excretion and toxicity (ADMET) 320 properties, these descriptors play key role. Basically, fraction of molecules like functional 321 322 group defines the probable properties of the drug. Molecular weight (MW), heavy atoms, aromatic heavy atoms, fraction of carbon having sp³ hybridization, no. of rotatable bonds, H-323 324 bond donors, H-bond acceptors, molar refractivity, topological surface area (TPSA) solubility (log S), distribution coefficient (log D_{7.4}) and partition coefficient (log P) were calculated 325 using the web server from the webserver (http://admet.scbdd.com/calcpre/index/). Based on 326 the physicochemical properties ADMET properties were calculated.[15, 21, 27, 63-65] 327 328


330 **References**

- 3311.Alfahan, A., et al., In the era of corona virus: health care professionals' knowledge,332attitudes, and practice of hand hygiene in Saudi primary care centers: a cross-sectional333study. J Community Hosp Intern Med Perspect, 2016. 6(4): p. 32151.
- 3342.Al-Hameed, F.M., Spontaneous intracranial hemorrhage in a patient with Middle East335respiratory syndrome corona virus. Saudi Med J, 2017. 38(2): p. 196-200.
- 3363.Al-Hazmi, A., Challenges presented by MERS corona virus, and SARS corona virus to global337health. Saudi J Biol Sci, 2016. 23(4): p. 507-11.
- 3384.Sahu, S., et al., In silico ADMET study, docking, synthesis and antimalarial evaluation of339thiazole-1,3,5-triazine derivatives as Pf-DHFR inhibitor. Pharmacological Reports, 2019.34071(5): p. 762-767.
- 3415.El Aissouq, A., et al., In Silico Design of Novel Tetra-Substituted Pyridinylimidazoles342Derivatives as c-Jun N-Terminal Kinase-3 Inhibitors, Using 2D/3D-QSAR Studies, Molecular343Docking and ADMET Prediction. International Journal of Peptide Research and344Therapeutics, 2019.
- 3456.Vian, M., et al., In silico model for mutagenicity (Ames test), taking into account346metabolism. Mutagenesis, 2019. 34(1): p. 41-48.
- 3477.Onen-Bayram, F.E., et al., 3-Propionyl-thiazolidine-4-carboxylic acid ethyl esters: a family348of antiproliferative thiazolidines. Medchemcomm, 2015. 6(1): p. 90-93.
- 3498.Kumar, P.P., et al., One pot, three-component synthesis of novel 3, 4-dihydrophthalazin-3502(1H)-yl-4-phenyl-4H-pyrans. Tetrahedron Letters, 2014. 55(14): p. 2177-2182.
- 3519.Patel, D.S., J.R. Avalani, and D.K. Raval, One-pot solvent-free rapid and green synthesis of3523,4-dihydropyrano[c]chromenes using grindstone chemistry. Journal of Saudi Chemical353Society, 2016. 20: p. S401-S405.
- 35410.Wang X. M., Y.H.L., Qaun Z. J., Wang X. C.,, One-pot synthesis of benzoquinoline and355coumarin derivatives using Meldrum's acid in three-component reactions. Res. Chem.356Intermed., 2013. 39(6): p. 2357–2367.
- 35711.Yavari, I., et al., A one-pot synthesis of bis(phenylimino)thiazolidines from ketene N,S-358acetals and N,N ',-diphenyloxalimidoyl dichloride. Molecular Diversity, 2018. 22(1): p. 11-35919.
- 36012.Yang, J.G., et al., One-pot three-component synthesis of tetrahydrobenzo[b]pyrans361catalyzed by cost-effective ionic liquid in aqueous medium. Chinese Journal of Chemical362Engineering, 2015. 23(8): p. 1416-1420.
- 36313.Singh, P., et al., Synthesis and electrochemical studies of charge-transfer complexes of364thiazolidine-2,4-dione with sigma and pi acceptors. Spectrochim Acta A Mol Biomol365Spectrosc, 2010. 75(3): p. 983-91.
- 36614.Kumar, A., et al., Nano-sized copper as an efficient catalyst for one pot three component367synthesis of thiazolidine-2, 4-dione derivatives. Catal Comm 2008. 10: p. 17-22.
- 36815.Ferreira, L.L.G. and A.D. Andricopulo, ADMET modeling approaches in drug discovery. Drug369Discovery Today, 2019. 24(5): p. 1157-1165.
- 37016.Babic, I., et al., Influence of flavonoids' lipophilicity on platelet aggregation. Acta371Pharmaceutica, 2019. 69(4): p. 607-619.
- 37217.Nanavati, C. and D.E. Mager, Calculated Log D Is Inversely Correlated With Select373Camptothecin Clearance and Efficacy in Colon Cancer Xenografts. Journal of374Pharmaceutical Sciences, 2016. 105(4): p. 1561-1566.
- 37518.Rodriguez-Rosales, R.J. and Y. Yao, Phytoglycogen, a natural dendrimer-like glucan,376improves the soluble amount and Caco-2 monolayer permeation of curcumin and enhances377its efficacy to reduce HeLa cell viability. Food Hydrocolloids, 2020. 100.
- 37819.Feldmann, M., et al., P-glycoprotein (Pgp) overactivity in pharmacoresistant epilepsy379patients with focal cortical dysplasia compared to healthy controls measured using (R)-


- [11C] verapamil PET and the Pgp inhibitor Tariquidar. European Journal of Neurology,
 2014. 21: p. 229-229.
- 38220.Ma, C.Y., et al., Prediction models of human plasma protein binding rate and oral383bioavailability derived by using GA-CG-SVM method. Journal of Pharmaceutical and384Biomedical Analysis, 2008. 47(4-5): p. 677-682.
- 38521.Wang, N.N., et al., ADME Properties Evaluation in Drug Discovery: Prediction of Caco-2 Cell386Permeability Using a Combination of NSGA-II and Boosting. Journal of Chemical387Information and Modeling, 2016. 56(4): p. 763-773.
- 38822.Bao, X., et al., Protein Expression and Functional Relevance of Efflux and Uptake Drug389Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma. Clinical390Pharmacology & Therapeutics, 2019.
- 39123.Rostkowski, M., O. Spjuth, and P. Rydberg, WhichCyp: prediction of cytochromes P450392inhibition. Bioinformatics, 2013. 29(16): p. 2051-2052.
- 39324.Su, B.H., et al., Rule-Based Prediction Models of Cytochrome P450 Inhibition. Journal of394Chemical Information and Modeling, 2015. 55(7): p. 1426-1434.
- 39525.Daina, A., O. Michielin, and V. Zoete, SwissADME: a free web tool to evaluate396pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.397Sci Rep, 2017. 7: p. 42717.
- Vishvakarma, V.K.S., P.; Kumar, V.; Kumari, K.; Patel, R.; Chandra, R.;, Pyrrolothiazolones
 as Potential Inhibitors for the nsP2B-nsP3 Protease of Dengue Virus and Their Mechanism of Synthesis. Chemistryselect, 2019. 4(32): p. 9410-9419.
- 40127.Guan, L.F., et al., ADMET-score a comprehensive scoring function for evaluation of402chemical drug-likeness. Medchemcomm, 2019. 10(1): p. 148-157.
- 40328.Celik, S., et al., Synthesis, molecular docking and ADMET study of ionic liquid as anticancer404inhibitors of DNA and COX-2, TOPII enzymes. Journal of Biomolecular Structure &405Dynamics, 2019. 7: p. 1-11.
- 40629.Deo, K.M., et al., Synthesis, characterisation and potent cytotoxicity of unconventional407platinum(iv) complexes with modified lipophilicity. Dalton Transactions, 2019. 48(46): p.40817217-17227.
- 40930.Di, L. and E.H. Kerns, Application of pharmaceutical profiling assays for optimization of410drug-like properties. Current Opinion in Drug Discovery & Development, 2005. 8(4): p. 495-411504.
- 41231.Hull, C.M., et al., Investigating the utility of adult zebrafish ex vivo whole hearts to413pharmacologically screen hERG channel activator compounds. American Journal of414Physiology-Regulatory Integrative and Comparative Physiology, 2019. 317(6): p. R921-415R931.
- 41632.Benfenati, E., et al., A large comparison of integrated SAR/QSAR models of the Ames test417for mutagenicity(\$). Sar and Qsar in Environmental Research, 2018. 29(8): p. 591-611.
- 41833.Wilm, A., et al., Skin Doctor: Machine Learning Models for Skin Sensitization Prediction419that Provide Estimates and Indicators of Prediction Reliability. International Journal of420Molecular Sciences, 2019. 20(19).
- 42134.Alvarez-Holguin, A., et al., Mean lethal dose (LD50) and growth reduction (GR(50)) due to422gamma radiation in Wilman lovegrass (Eragrostis superba). Revista Mexicana De Ciencias423Pecuarias, 2019. 10(1): p. 227-238.
- 42435.Mullins, C., K. Beaulac, and L. Sylvia, Drug-Induced Liver Injury (DILI) With Micafungin: The425Importance of Causality Assessment. Annals of Pharmacotherapy, 2019.
- 42636.Liu, T., et al., Estimation of Maximum Recommended Therapeutic Dose Using Predicted427Promiscuity and Potency. Cts-Clinical and Translational Science, 2016. 9(6): p. 311-320.
- 428 37. Branham, M.L., E.A. Ross, and T. Govender, *Predictive Models for Maximum* 429 *Recommended Therapeutic Dose of Antiretroviral Drugs.* Computational and Mathematical
 430 Methods in Medicine, 2012.

- 431 38. Frisch, M.J.T., G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; 432 Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. 433 V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; 434 Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; 435 Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; 436 Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; 437 Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; 438 Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; 439 Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; 440 Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; 441 Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, 442 J. B.; Fox, D. J., Gaussian 16, Revision C.01. 2016. 443 Vishvakarma, V.K., K. Kumari, and P. Singh, A Model To Study The Inhibition Of Arginase II 39. 444 With Noscapine & Its Derivatives. J Pro Res Bioinf 2020. 2(1): p. 1-14.
- 44540.Kumar, D., et al., Development of a theoretical model for the inhibition of nsP3 protease of446Chikungunya virus using pyranooxazoles. J Biomol Struct Dyn, 2020. 30(10): p. 3018-3034.
- 447 41. Vishvakarma, V.K., et al., *Pyrrolothiazolones as Potential Inhibitors for the nsP2B-nsP3*448 *Protease of Dengue Virus and Their Mechanism of Synthesis* ChemistrySelect 2019. 4(32):
 449 p. 9410-9419.
- 450 42. Vishvakarma, V.K., et al., A model to study the inhibition of nsP2B-nsP3 protease of dengue
 451 virus with imidazole, oxazole, triazole thiadiazole, and thiazolidine based scaffolds.
 452 Heliyon, 2019. 5(8): p. e02124.
- 45343.Singh, P., et al., Computational approach to study the synthesis of noscapine and potential454of stereoisomers against nsP3 protease of CHIKV. Heliyon, 2019. 5(12): p. e02795.
- 45544.Yang, J.M. and C.C. Chen, GEMDOCK: A generic evolutionary method for molecular456docking. Proteins-Structure Function and Bioinformatics, 2004. 55(2): p. 288-304.
- 457 45. Kumar, D., et al., Promising inhibitors of main protease of novel corona virus to prevent
 458 the spread of COVID-19 using docking and molecular dynamics simulation. J Biomol Struct
 459 Dyn, 2020: p. 1-15.
- 460
 46. Kumar, D., et al., Selective Docking of Pyranooxazoles Against nsP2 of CHIKV Eluted
 461
 461 Through Isothermally and Non-Isothermally MD simulations. ChemistrySelect, 2020. 5(14):
 462
 p. 4210-4220.
- 463 47. Kumar, D., et al., Understanding the binding affinity of noscapines with protease of SARS 464 CoV-2 for COVID-19 using MD simulations at different temperatures. J Biomol Struct Dyn,
 465 2020: p. 1-14.
- 46648.Kumar, D., et al., A Theoretical Model to Study the Interaction of Erythro-Noscapines with467nsP3 protease of Chikungunya Virus ChemistrySelect 2019. 4(17): p. 4892-4900.
- 46849.Vishvakarma, V.K., et al., Rational Design of Threo as Well Erythro Noscapines, an469Anticancer Drug: A Molecular Docking and Molecular Dynamic Approach Biochemistry &470Pharmacology 2017. 6(3): p. 1-7.
- 47150.Vishvakarma, V.K., et al., Interaction between Bovine Serum Albumin and Gemini472Surfactants using Molecular Docking Characterization Inf Sci Lett, 2017. 3: p. 1-9.
- 47351.Singh, P., et al., Computational docking studies of Noscapines: A potential bioactive agent474Amer J Pharmacol Pharmacother, 2017. 4(1): p. 9-14.
- 47552.Kumar, D., et al., Impact of Gemini Surfactants on the stability of Insulin using476computational tools J Nanomed Biother 2017. 7: p. 1-5.
- 47753.Singh, P., K. Kumari, and R. Chandra, Green synthesis of Tetrazines and their role as human478cytomegalovirus (HCMV) protease inhibitor J Theor Comp Sci 2016. 3: p. 1-5.
- Singh, P., K. Kumari, and R. Chandra, Synthesis, Computational & Docking Studies of Bis-(4 Hydroxycoumarin-3-YI) Methanes As Potential Inhibitor For Carbonic Anhydrase,
 Glyceraldehyde-3-Phosphate Dehydrogenase J Pharm App Chem 2016. 2: p. 81-101.


- 48255.Singh, P., et al., Virtual Screening and Docking Studies of Synthesized Chalcones: Potent483Anti-Malarial Drug Inter J Drug Dev Res 2016. 8(1): p. 49-56.
- 484 56. Patel, R., et al., Interaction between pyrolidium based ionic liquid and bouvine serum
 485 albumin: A Spectroscopic and molecular docking insight Biochem Anal Biochem 2016. 5: p.
 486 1-8.
- 487 57. Chakravarty, A.K., P. Singh, and K. Kumari, One pot green synthesis of biological potent
 488 thiazolopyrans and docking against human pancreatic lipase related protein 1 receptors
 489 Inter J Curr Adv Res 2016. 5(1): p. 559-563.
- 490 58. Vishvakarma, V.K., et al., *Theoretical model to investigate the alkyl chain and anion*491 *dependent interactions of gemini surfactant with bovine serum albumin.* Spectrochim Acta
 492 A Mol Biomol Spectrosc, 2015. 143: p. 319-23.
- 49359.Shareef, M.A., et al., Design, synthesis, and antimicrobial evaluation of 1,4-494dihydroindeno[1,2-c]pyrazole tethered carbohydrazide hybrids: exploring their in silico495ADMET, ergosterol inhibition and ROS inducing potential. Medchemcomm, 2019. 10(5): p.496806-813.
- 49760.Hsu, K.C., et al., *iGEMDOCK: a graphical environment of enhancing GEMDOCK using*498*pharmacological interactions and post-screening analysis.* Bmc Bioinformatics, 2011. 12.
- 49961.Vijay, K.V., K. Kamlesh, and S. Prashant, Inhibition of Protease of Novel Corona Virus by500Designed Noscapines: Molecular Docking and ADMET Studies. ChemRxiv, 2020.
- 50162.Durgesh, K., K. Kamlesh, and S. Prashant, A Theoretical Model to Study the Interaction502Between Boronic Acids and Insulin. ChemRxiv, 2020.
- 50363.Tian, S., et al., ADME Evaluation in Drug Discovery. 9. Prediction of Oral Bioavailability in504Humans Based on Molecular Properties and Structural Fingerprints. Molecular505Pharmaceutics, 2011. 8(3): p. 841-851.
- 50664.Wu, Z.X., et al., ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human507Cytochrome P450 Inhibition Using Artificial Intelligence Approaches. Journal of Chemical508Information and Modeling, 2019. 59(11): p. 4587-4601.
- 50965.Yang, H.B., et al., admetSAR 2.0: web-service for prediction and optimization of chemical510ADMET properties. Bioinformatics, 2019. 35(6): p. 1067-1069.
- 511
- 512




515 Scheme 1 Synthesis of 7516 d]thiazole-6,9-dione




521 Scheme 2 Proposed mechanism of synthesis of 7-phenyl-7,10-dihydro-6H,9H522 chromeno[3',4':5,6]pyrano[2,3-d]thiazole-6,9-dione i.e. thiazolidinones



- 526 Figure 1 Analysis for the mechanism for the synthesis of 7-phenyl-7,10-dihydro-6H,9H-
- 527 chromeno[3',4':5,6]pyrano[2,3-d]thiazole-6,9-dione as in **Scheme 2**







530 Figure 2 docked posed of compounds 34, 42, 55, 58, 60 and 93 with the protease of SARS-

531 COV-2





Table 1 HOMO, LUMO optimized geometry & energies values of the reactants,
intermediates and product as in Scheme 2



5.N.		Substituent's	positions on aryl part	t of aldehyd	le
	2	3	4	5	6
0	-H	-H	-H	-H	-H
1	-H	-OMe	-O-CH ₂ -CH ₂ -Br	-H	-H
2	-H	-OMe	-OMe	-OMe	-Br
3	-Br	-H	-H	-OMe	-OH
4	-NH ₂	-Br	-H	-Br	-H
5	-OMe	-Br	-H	-Br	-H
6	-OH	-Br	-H	-Br	-H
7	-H	-Br	-OH	-Br	-H
8	-H	-Cl	-OH	-Br	-H
9	-H	-Br	-OMe	-Br	-H
10	-H	-OMe	-OMe	-Br	-H
11	-H	-OMe	-OH	-Br	-H
12	-OH	-Br	-H	-Cl	-H
13	-OH	-Br	-H	-NO ₂	-H
14	-H	-H	-OMe	-OH	-Br
15	-OH	-Br	-H	-H	-H
16	-OH	-O-C ₂ H ₅	-H	-Br	-Br
17	-OMe	-H	-OMe	-Br	-H
18	-OMe	-H	-OH	-Br	-H
19	-Br	-H	-OMe	-OMe	-H
20	-Br	-H	-OMe	-OH	-H
21	-Br	-H	-H	-Br	-H
22	-H	-NO ₂	-Br	-H	-H
23	-Br	-H	-H	-OMe	-H
24	-Br	-H	-H	-OH	-H
25	-Br	-H	-CH ₃	-H	-H
26	-H	-H	-CH ₃	-Br	-H
27	-H	-H	-OMe	-Br	-H
28	-H	-H	-OH	-Br	-H
29	-Br	-H	-Cl	-H	-H
30	-Br	-H	-OMe	-H	-H
31	-Br	-CHO	-H	-H	-H
32	-Br	-H	-H	-H	-H
33	-OMe	-OMe	-H	-Br	-H
34	-OH	-NO ₂	-H	-Br	-H
35	-OH	-OMe	-H	-Br	-H
36	-NO ₂	-H	-Br	-H	-H
37	-OMe	-H	-Br	-H	-H
38	-OH	-H	-Br	-H	-H
39	-H	-Br	-H	-H	-OH

Table 2 Designing the library of thiazolidinones on varying the aromatic aldehyde

40	-H	-Br	-H	-Br	-H
41	-H	-Cl	-H	-Cl	-H
42	-Н	-NO ₂	-Н	-Br	-H
43	-H	-Br	-H	-H	-H
44	-Н	-H	-Br	-H	-H
45	-H	-H	$-N(C_2H_4Cl)_2$	-H	-H
46	-Cl	-H	-OMe	-OMe	-Cl
47	-H	-OMe	-OMe	-Cl	-H
48	-H	-OMe	-OH	-Cl	-H
49	-OH	-Cl	-H	-Cl	-H
50	-H	-H	-OMe	-OMe	-Cl
51	-H	-H	-OMe	-OH	-Cl
52	-Cl	-H	-H	-H	-CH ₃
53	-OH	-Cl	-H	-H	-H
54	-Cl	-H	-H	-H	-Cl
55	-Cl	-H	-Н	-H	-NO ₂
56	-Cl	-Н	-Н	-H	-OH
57	-H	-Cl	-Cl	-Cl	-H
58	-H	$-NO_2$	-Cl	-H	-H
59	-Cl	-H	-H	-Cl	-H
60	-Cl	-H	-Н	-NO ₂	-H
61	-Cl	-H	-H	-Cl	-Cl
62	-Cl	-H	-Me	-H	-H
63	-H	-H	-Me	-Cl	-H
64	-H	-H	-Cl	-Cl	-H
65	-H	-H	-OMe	-Cl	-H
66	-H	-H	-OH	-Cl	-H
67	-Cl	-H	-Cl	-H	-H
68	-Cl	-H	-OH	-H	-H
69	-Cl	-Cl	-H	-H	-H
70	-Cl	-OMe	-H	-H	-H
71	-Cl	-OH	-H	-H	-H
72	-Cl	-H	-H	-H	-H
73	-OMe	-OMe	-H	-Cl	-H
74	-OH	-OMe	-H	-Cl	-H
75	-NO ₂	-H	-Cl	-H	-H
76	-OMe	-H	-Cl	-H	-H
77	-H	-Cl	-H	-H	NO ₂
78	-H	-Cl	-H	-H	-OH
79	-H	-Cl	-H	-Cl	-H
80	-H	-Cl	-H	-H	-H
81	-H	-H	-Cl	-H	-H
82	-Cl	-CF ₃	-H	-H	-H

83	-F	-CF ₃	-H	-H	-H
84	-CF ₃	-H	-H	-H	-F
85	-CF ₃	-H	-H	-CF ₃	-H
86	-CF ₃	-H	-CF ₃	-H	-H
87	-H	-H	-Cl	-CF ₃	-H
88	-H	-H	-F	-CF ₃	-H
89	-CF ₃	-H	-F	-H	-H
90	-CF ₃	-H	-H	-H	-H
91	-F	-Cl	-H	-CF ₃	-H
92	-F	-H	-CF ₃	-H	-H
93	-NO ₂	-H	-CF ₃	-H	-H
94	-H	-CF ₃	-H	-H	-Cl
95	-H	-CF ₃	-H	-H	-F
96	-H	-CF3	-H	-CF ₃	-H
97	-H	-F	-H	-CF ₃	-H
98	-H	-CF ₃	-H	-H	-H
99	-H	-H	-CF ₃	-H	-H
100	-O-CF ₃	-H	-H	-H	-H

Table 3 Binding energy of the designed molecules i.e. thiazolidinones (0-99) against the

⁵⁴² protease of SARS-COV-2

C. No.	Total Energy						
0	-103.55	25	-104.031	50	-111.603	75	-123.204
1	-107.701	26	-106.624	51	-113.964	76	-113.278
2	-121.514	27	-106.881	52	-105.448	77	-115.895
3	-118.534	28	-107.273	53	-112.021	78	-107.294
4	-109.654	29	-110.676	54	-115.149	79	-109.432
5	-118.41	30	-110.686	55	-127.526	80	-105.223
6	-109.743	31	-119.633	56	-111.264	81	-105.202
7	-107.148	32	-99.8576	57	-107.673	82	-109.748
8	-106.913	33	-117.99	58	-124.746	83	-115.729
9	-108.296	34	-128.6	59	-102.491	84	-114.573
10	-109.287	35	-112.327	60	-135.77	85	-118.683
11	-105.056	36	-116.326	61	-104.549	86	-123.132
12	-110.761	37	-111.994	62	-106.168	87	-113.923
13	-117.551	38	-110.746	63	-108.138	88	-107.365
14	-111.07	39	-108.884	64	-106.497	89	-112.351
15	-110.399	40	-101.055	65	-107.46	90	-112.544
16	-113.723	41	-106.873	66	-105.802	91	-109.986
17	-106.56	42	-126.715	67	-97.7663	92	-109.529
18	-120.263	43	-106.497	68	-112.609	93	-129.464
19	-120.304	44	-105.14	69	-108.201	94	-100.907
20	-114.991	45	-110.747	70	-113.226	95	-109.487
21	-112.805	46	-111.338	71	-122.674	96	-111.982
22	-122.622	47	-104.723	72	-108.422	97	-112.753
23	-117.902	48	-110.12	73	-117.525	98	-113.016
24	-114.44	49	-100.534	74	-110.906	99	-109.837

Table 4 Compounds number 34, 42, 55, 58, 60 and 93 showed the best binding with the
protease of SARS-COV-2

C. No.	Total Energy	Evdw	E_{HBond}	E _{Elec}
60	-135.77	-92.5376	-44.2146	0.982384
93	-129.464	-117.664	-12.3849	0.58528
34	-128.6	-100.732	-28.8356	0.967276
55	-127.526	-104.378	-22.5981	-0.54959
42	-126.715	-86.5302	-40.9819	0.797261
58	-124.746	-90.5023	-35.1325	0.889179

- **Table 4a** Binding energy of the repurposing drugs against the protease of SARS-COV-2 used
- 550 in clinical trials

Compound name	T. Energy	VDW	HBond	Elec
N3	-116.132	-104.716	-11.4159	0
Camostat	-114.554	-94.6993	-17.4391	-2.41559
Remdesivir	-105.955	-82.4292	-23.5262	0
Baricitinib	-94.5708	-62.9297	-31.641	0
Favipiravir	-93.8858	-57.7481	-36.1377	0
Galidesivir	-91.6304	-59.05	-32.5804	0
Darunavir-2	-91.3952	-73.1994	-18.1957	0
Thalidomide	-88.7425	-69.6454	-19.097	0
Cobicistat	-83.7343	-74.1677	-9.56651	0
Ruxolitinib	-82.5082	-71.6024	-10.9059	0
Fingolimod	-75.6867	-60.3308	-15.3559	0
Hydroxychloroquine	-74.8428	-66.1241	-8.71866	0
Chloroquine	-73.894	-65.431	-8.463	0
Arbidol	-69.6036	-63.6572	-5.9464	0

Table 5 Interaction (hydrogen bonds and hydrophobic) of the top six compounds with
different amino-acids of the protease of SARS-COV-2

Ligand	ŀ	l-Bond	Hydrophobic			
	Amino Acid	Distance	Amino Acid	Distance		
60	SER 144	2.94	CYS 145	5.01; 5.49; 5.20; 5.04		
	GLY 143	2.25	HIS 41	4.28		
	CYS 145	2.46; 2.02	MET 165	5.37		
			LEU 27	5.41		
93	SER 144	2.87	GLN 189	2.78		
	CYS 145	2.74	MET 165	4.92; 4.34		
			CYS 145	5.49;		
			LEU 27	4.13		
34	HIS 164	2.47	MET 165	5.27		
	SER 144	1.78	HIS 41	4.70		
	GLY 143	1.84; 2.88	CYS 145	4.13		
	ASN 142	3.02	LEU 27	4.88		
	CYS 145	2.30				
55	GLU 166	2.90	HIS 41	4.88		
	SER 144	2.33	LEU 27	4.75		
	CYS 145	2.24; 2.45	CYS 145	4.30		
42	CYS 145	2.51; 1.90	HIS 172	5.09		
	HIS 164	3.12	HIS 163	5.48		
	GLY 143	2.51	HIS 41	4.67		
	SER 144	2.02	LEU 27	5.42		
			CYS 145	4.98; 5.49; 5.22		
58	CYS 145	2.22	MET 49	5.44		
	SER 144	2.46	HIS 41	4.52; 4.63		
	GLY 143	2.78	CYS 145	5.46		
			MET 165	4.46		
			HIS 163	3.72		
			HIS 172	4.91		
			PHE 140	5.01		

Table 6 LogS, LogD7.4 and LogP of the top six compounds

Property	60	93	34	55	42	58
Log S	-4.558	-4.664	-4.23	-4.581	-4.57	-4.558
LogD _{7.4}	2.754	2.728	0.958	2.702	2.765	2.754
LogP	3.908	4.274	3.723	3.908	4.018	3.908

93 55 42 Property 60 34 58 Papp (Caco-2 Permeability) -4.566 -4.525 -4.549 -4.731 -4.528 -4.549 Pgp-inhibitor 0.638 0.294 0.67 0.638 0.473 0.712 Pgp-substrate 0.036 0.09 0.033 0.042 0.086 0.036 HIA (Human Intestinal Absorption) 0.671 0.67 0.671 0.651 0.671 0.568F (20% Bioavailability) 0.662 0.64 0.662 0.662 0.649 0.649 F (30% Bioavailability) 0.533 0.384 0.533 0.483 0.527 0.523

560 Table 7 Absorption properties of the top six thiazolidinones

Table 8 Distribution properties of top six thiazolidinones

Property	60	93	34	55	42	58
PPB (%)	91.44	92.921	91.162	90.991	91.769	91.44
VD (L/kg)	-0.713	-0.892	-1.170	-0.702	-0.782	-0.713
BBB	0.615	0.679	0.269	0.788	0.647	0.615

Property	60	93	34	55	42	58
P450 CYP1A2 inhibitor	0.591	0.615	0.608	0.68	0.678	0.591
P450 CYP1A2 Substrate	0.558	0.558	0.466	0.56	0.481	0.558
P450 CYP3A4 inhibitor	0.577	0.58	0.526	0.5	0.634	0.577
P450 CYP3A4 substrate	0.514	0.484	0.504	0.526	0.55	0.514
P450 CYP2C9 inhibitor	0.684	0.657	0.747	0.6	0.725	0.684
P450 CYP2C9 substrate	0.424	0.484	0.487	0.49	0.468	0.424
P450 CYP2C19 inhibitor	0.597	0.563	0.53	0.544	0.64	0.597
P450 CYP2C19 substrate	0.53	0.522	0.517	0.564	0.566	0.53
P450 CYP2D6 inhibitor	0.425	0.37	0.392	0.396	0.426	0.425
P450 CYP2D6 substrate	0.391	0.461	0.372	0.392	0.315	0.391

Table 9 Metabolism properties of top six thiazolidinones

Table 10 Excretion properties of top six thiazolidinones

Property	60	93	34	55	42	58
T 1/2 (Half Life Time)	1.635	1.714	1.538	1.647	1.595	1.635
CL (Clearance Rate) mL/min/kg	1.075	1.104	1.007	1.022	0.943	1.075

Table 11 Toxicity properties of top six thiazolidinones

Property	60	93	34	55	42	58
hERG (hERG Blockers)	0.464	0.52	0.463	0.475	0.5	0.464
H-HT (Human Hepatotoxicity)	0.79	0.768	0.816	0.76	0.774	0.79
AMES (Ames Mutagenicity)	0.874	0.782	0.868	0.874	0.886	0.874
SkinSen (Skin sensitization)	0.561	0.476	0.546	0.561	0.545	0.561
LD50 (LD50 of acute toxicity)	2.831	3.604	3.052	2.863	3.072	2.831
DILI (Drug Induced Liver Injury)	0.898	0.902	0.89	0.898	0.884	0.898
FDAMDD (Maximum Recommended	0.502	0.43	0.4	0.416	0.454	0.502
Daily Dose)						